Shots:

• The REALITI-A study involves assessing of Nucala (100mg- SC) in 368 patients with severe eosinophilic asthma- being conducted in a routine care setting- compared to the prior 12mos.
• The REALITI-A study results: annual reduction rate in exacerbations (69%); reduction in exacerbations requiring hospitalization/emergency room visits (77%); reduction in m-oral corticosteroid (OCS) dose 10 mg/day to 5mg/day with 34% of patients able to stop OCS completely- study is expected to be completed in 2021
• Nucala is mAb targeting IL-5- prevent its binding to its receptor on the surface of eosinophils- reducing blood eosinophils without completely depleting them and is an approved therapy in the US- EU & 20+ countries as an add-on maintenance treatment for patients with SEA

Click here to­ read full press release/ article 

Ref: GSK | Image: GSK